Table 2

Mean (SD) CPG intensity, median (IQR) CPG disability and count CPG grade at baseline, 6-month follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU)

 PrescribingReviewTAUp Value (between groups†)
N*Mean (SD)N*Mean (SD)N*Mean (SD)
Baseline CPG intensity4766.1 (16.0)4568.4 (17.6)5465.4 (18.0)
6-month follow-up CPG intensity58.1 (19.5)67.4 (21.7)65.6 (19.6)
Difference CPG intensity−8.0 (16.3)−1.0 (16.0)0.2 (14.9)
p (within groups‡)0.0020.670.930.02
Effect size (r)0.450.070.01
Median (IQR)Median (IQR)Median (IQR)
Baseline CPG disability4860.0 (30.0;75.8)4666.7 (45.0;80.0)5356.7 (36.7;80.0)
6-month follow-up CPG disability40.0 (20.0;60.0)53.3 (29.2;73.3)50.0 (25.0;80.0)
Difference CPG disability−8.3 (−23.3;0.0)−3.3 (−16.7;10.0)−3.3 (−21.7;5.0)
p (within groups‡)0.0030.150.050.55
Effect size (r)0.430.200.26
Baseline CPG grade44Count (%)44Count (%)48Count (%)
 I5 (11.4)3 (6.8)5 (10.4)
 II16 (36.4)9 (20.5)13 (27.1)
 III7 (15.9)10 (22.7)13 (27.1)
 VI16 (36.4)22 (50.0)17 (35.4)
6-month follow-up CPG grade
 I13 (29.5)8 (18.2)6 (12.5)
 II13 (29.5)15 (34.1)17 (35.4)
 III8 (18.2)8 (18.2)11 (22.9)
 IV10 (22.7)13 (29.5)14 (29.2)
Difference CPG grade
 ≤−121 (47.7)17 (38.6)15 (31.2)
 017 (38.6)25 (56.8)25 (52.1)
 ≥16 (13.6)2 (4.5)8 (2.1)0.16
p (within groups†)0.0030.0010.17
  • p Values for within-arm and between-arm differences are also reported.

  • *Number of participants in each group who completed the appropriate part of the CPG at both baseline and follow-up.

  • †From analysis of variance on mean difference, Kruskall-Wallis on median difference or χ2 test on difference in CPG grade as appropriate.

  • ‡From paired t test, Wilcoxon signed rank test or marginal homogeneity test as appropriate.

  • CPG, Chronic Pain Grade.